Samsung Biologics to buy Switzerland's PolyPeptide in $1.8B deal
What's the deal? Samsung BiologicsDealroom has a profile for this one. Try Dealroom → has launched an all-cash public tender offer to acquire 100% of Switzerland's PolyPeptide GroupDealroom has a profile for this one. Try Dealroom → at CHF 44.31 per share — an equity value of about CHF 1.46 billion (~$1.8 billion). The price is a 40% premium to PolyPeptide's undisturbed closing price of CHF 31.65 before acquisition rumours surfaced in April 2026. The offer is backed by a unanimous recommendation from PolyPeptide's independent board members and an irrevocable undertaking from its largest shareholder, who holds roughly 55.65% of the shares.
Why now? PolyPeptide is a specialist contract development and manufacturing organisation (CDMO) for peptide-based active pharmaceutical ingredients, with more than 70 years of heritage, over 1,000 therapeutic peptides produced, and six GMP-certified sites across Sweden, Belgium, France, the US and India. The deal pushes Samsung Biologics beyond antibodies and ADCs into peptide therapeutics — one of the fastest-growing corners of biopharma, driven by surging demand for GLP-1 obesity and diabetes drugs.
What it means: The acquisition extends Samsung Biologics' multi-modality CDMO platform and its manufacturing footprint across the US, Europe and India. Once the offer completes — expected toward the end of 2026, subject to a two-thirds minimum acceptance threshold and regulatory approvals — Samsung intends to squeeze out remaining minority shares and delist PolyPeptide from the SIX Swiss Exchange, making it a wholly owned subsidiary. J.P. Morgan is acting as exclusive financial advisor to Samsung Biologics.
Read more: CNBC · PR Newswire
